Market Research Report
Biliary Atresia (BA) - Epidemiology Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||955320|
|Published||Content info||100 Pages
Delivery time: 1-2 business days
|Biliary Atresia (BA) - Epidemiology Forecast - 2030|
|Published: August 1, 2020||Content info: 100 Pages||
DelveInsight's 'Biliary Atresia (BA)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Biliary Atresia (BA) Disease Understanding
Biliary Atresia (BA) Overview
Biliary Atresia is a neonatal liver disease characterized by progressive obstruction and fibrosis of the extrahepatic biliary tree along with fibrosis and inflammation of the liver parenchyma. The etiology and pathogenesis of BA remain unknown. Recent studies are examining potential pathogenetic mechanisms of BA, including genetic susceptibility, the involvement of the immune system, and environmental insults such as viruses and toxins. It is possible that there is not a single etiological agent but rather a large group of injurious insults that might result in a final common pathway of extrahepatic bile duct obstruction and liver fibrosis.
The symptoms of biliary atresia usually appear by the age of 2-6 weeks. They include a yellowish coloration of the skin and whites of the eyes (jaundice), abnormally pale stools, and dark urine. Infants may also have swollen (distended) stomach and/or abnormal enlargement of the liver (hepatomegaly). The pathway from clinical suspicion to establishing the diagnosis of biliary atresia in a child with jaundice is a daunting task-however, investigations available help point the correct diagnosis in a reasonable time frame.Imaging by sonography has identified several parameters which can be of help in the diagnostic workup. Comparison of sonography with imaging by nuclear medicine can bring out significant differences and also avoid inappropriate imaging. The battery of biochemical tests, available currently, enable a better understanding of the line-up of investigations in a given child with neonatal cholestasis. Untreated, biliary atresia remains a fatal condition of the newborn. Most present within 4-6 weeks of conjugated jaundice and acholic stools, and although still a challenging diagnosis to make, therein lies the opportunity of changing the course of this otherwise inexorable disease.
The Biliary Atresia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Atresia epidemiology segmented as the Total Incident Cases of Biliary Atresia, Type-specific Cases of Biliary Atresia, and Gender-specific Cases of Biliary Atresia. The report includes the Incident scenario of Biliary Atresia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the Biliary Atresia (BA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total Incident population of Biliary Atresia in the 7MM countries was estimated to be 613 in 2017.
As per the estimates, the United States has the highest Incident population of Biliary Atresia.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
The Biliary Atresia (BA) Epidemiology report will allow the user to -
Study Period: 2017-2030
The Biliary Atresia Research Consortium in the USA, the European Biliary Atresia Registry in Europe, and the Japanese Biliary Atresia Registry (JBAR) have been formed to help with data collection and provide a platform for large research studies.